Price movement over the last 24 hours
Alcon AG vs Essex Property Trust, Inc. — how do they compare? Alcon AG trades at $66.81 (market cap $32.69B), while Essex Property Trust, Inc. trades at $292.18 (market cap $19.17B). The key difference: Alcon AG is the larger of the two by market cap, and Essex Property Trust, Inc. pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| ALC | ESS | |
|---|---|---|
Market Cap | $32.69B | $19.17B |
Sector | Health | Real Estate |
52-Week High | $92.22 | $298.33 |
52-Week Low | $62.02 | $239.61 |
Enterprise Value | $36.28B | $25.89B |
Dividend Yield | 0.54% | 3.47% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Essex Property Trust (ESS) trades at $298.32, showing minimal daily change. The stock exhibits a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported robust earnings, beating estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.47. Revenue reached $1.89B in 2025, supported by high gross and net income margins. Recent developments include a $2.59 dividend declaration and inclusion in the Russell Microcap Index.
Outlook remains positive due to strong West Coast rental demand and AI-driven employment growth, but risks include high debt levels and Seattle market weakness. Analyst consensus is mixed with a $291.68 price target, suggesting limited upside from current levels. Investment appeal hinges on sustained rental growth and balance sheet management amid economic uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →